Investing in MENA to expand access and drive growth
Annual Report 2025
Case study
Our purpose in action
In the MENA region, where we leverage our global expertise locally, Hikma is the largest pharmaceutical company by sales1. Today, we have a broad portfolio of 430 products and an extensive pipeline that is supported by internal R&D and partnerships. In 2025, we launched 40 new products improving access to world-class medicines in the region. We also introduced non-invasive blood-based liquid biopsy technology for colorectal cancer screening. Across our markets, we are focused on building leading positions in key therapy areas such as oncology, cardiovascular, diabetes and multiple sclerosis, while also introducing broader healthcare solutions.
Capabilities driving success
Our success is built on trusted relationships with healthcare professionals, pharmacists, hospitals, and regulators combined with deep local knowledge. With 5,700+ colleagues and 20 manufacturing plants, we ensure reliable supply of medicines across the region. Our proven track record makes us the partner of choice for global companies that operate without a footprint in the region. Today, we manage over 110 products with around 60 partners who entrust us with manufacturing, registering, and commercialisation, reflecting confidence in Hikma as a trusted healthcare leader in MENA. Our R&D hub in Jordan, with two specialised centres dedicated to innovative product development, further strengthens our ability to deliver tailored solutions for long-term growth.
Expanding access through partnerships
In 2025, we diversified our partnerships to enhance patient access:
- Celltrion: Expanded biosimilar access across MENA
- pharma&: Exclusive oncology licensing agreement
- M42: Strategic MoU to advance diagnostics and digital tools in the UAE
- DGI Group: Licensing agreement to commercialise Claritag®, an OTC skin tag removal device
Engaging healthcare professionals We hosted and sponsored several platforms reaching 6,000+ healthcare professionals to deepen medical knowledge, while engaging patient advocacy groups in areas such as multiple sclerosis, cardiovascular disease, and diabetes. Through our direct-to-consumer platform Hiyat Hilweh, we continue to raise awareness of prevalent conditions, helping patients make better health choices. All our events and sponsorships are carefully overseen by the compliance function.
“Hikma is the trusted partner of choice in MENA. By combining global expertise with local capabilities, we deliver innovative medicines and technologies that improve lives and address the region’s health challenges.”
Mazen Darwazah
Executive Vice Chairman and Deputy CEO, MENA
1 Based on internal analysis by Hikma Pharmaceuticals PLC using data from the following source: IQVIA MIDAS® Monthly Value Sales data for the countries* listed above for the period: MAT November 2025, reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved. Countries included in MENA Region – Algeria, Egypt, Jordan, Kuwait, Lebanon, Morocco, Saudi Arabia, Tunisia and UAE